RU2576611C2 - Способы применения производных циклического амида для лечения шизофрении - Google Patents

Способы применения производных циклического амида для лечения шизофрении Download PDF

Info

Publication number
RU2576611C2
RU2576611C2 RU2013107382/15A RU2013107382A RU2576611C2 RU 2576611 C2 RU2576611 C2 RU 2576611C2 RU 2013107382/15 A RU2013107382/15 A RU 2013107382/15A RU 2013107382 A RU2013107382 A RU 2013107382A RU 2576611 C2 RU2576611 C2 RU 2576611C2
Authority
RU
Russia
Prior art keywords
schizophrenia
compound
symptom
sleep
subject
Prior art date
Application number
RU2013107382/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2013107382A (ru
Inventor
Реми Анри ЛУТРИНГЕР
Лоренцо ПЕЛЛЕГРИНИ
Аргерис Н. КАРАБЕЛАС
Original Assignee
Сиренейк Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиренейк Фармасьютикалз, Инк. filed Critical Сиренейк Фармасьютикалз, Инк.
Publication of RU2013107382A publication Critical patent/RU2013107382A/ru
Application granted granted Critical
Publication of RU2576611C2 publication Critical patent/RU2576611C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0003—Two-dimensional division
    • H04L5/0005—Time-frequency
    • H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2013107382/15A 2010-07-20 2011-07-20 Способы применения производных циклического амида для лечения шизофрении RU2576611C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
US61/366,075 2010-07-20
PCT/US2011/044697 WO2012012542A1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia

Publications (2)

Publication Number Publication Date
RU2013107382A RU2013107382A (ru) 2014-08-27
RU2576611C2 true RU2576611C2 (ru) 2016-03-10

Family

ID=45497166

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013107382/15A RU2576611C2 (ru) 2010-07-20 2011-07-20 Способы применения производных циклического амида для лечения шизофрении

Country Status (22)

Country Link
US (3) US20180155318A1 (enExample)
EP (4) EP3335731B1 (enExample)
JP (2) JP6053678B2 (enExample)
KR (1) KR101867633B1 (enExample)
CN (1) CN103220910B (enExample)
BR (1) BR112013001303A2 (enExample)
CA (2) CA2806017C (enExample)
DK (2) DK2595484T3 (enExample)
ES (2) ES2963362T3 (enExample)
FI (1) FI3135286T3 (enExample)
HR (1) HRP20231446T1 (enExample)
HU (1) HUE064157T2 (enExample)
LT (1) LT3135286T (enExample)
NO (1) NO2595484T3 (enExample)
PL (2) PL3135286T3 (enExample)
PT (2) PT3135286T (enExample)
RS (1) RS64819B1 (enExample)
RU (1) RU2576611C2 (enExample)
SI (1) SI3135286T1 (enExample)
SM (1) SMT202300413T1 (enExample)
TW (1) TWI583679B (enExample)
WO (1) WO2012012542A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2812901C2 (ru) * 2017-06-21 2024-02-05 Минерва Ньюросайенсиз, Инк. Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) * 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
GB202416895D0 (en) * 2024-11-18 2025-01-01 Phytoquest Ltd Treatment of sleep disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152440A (ru) * 2006-05-30 2010-07-10 Элбион Гмбх (De) ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152440A (ru) * 2006-05-30 2010-07-10 Элбион Гмбх (De) ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUTHEIL F et al. "Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putatine roles in cerebral function". Drug Metab Dispos 2009 Jul;37(7):1528-38, реферат, найдено 27.04.2015, найдено из PubMed PMID:19359404. YANG C et al. "Clinical significance of sleep EEG abnormalities in chronic schizophrenia". Schizophr Res. 2006 Feb 28;82(2-3):251-60, реферат, найдено 27.04.2015, найдено из PubMed PMID: 16377158. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2812901C2 (ru) * 2017-06-21 2024-02-05 Минерва Ньюросайенсиз, Инк. Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением

Also Published As

Publication number Publication date
SI3135286T1 (sl) 2024-02-29
DK3135286T3 (da) 2023-11-27
EP2595484A1 (en) 2013-05-29
BR112013001303A2 (pt) 2016-05-17
CA2806017C (en) 2021-06-29
EP4494704A2 (en) 2025-01-22
CA3117855A1 (en) 2012-01-26
RU2013107382A (ru) 2014-08-27
CN103220910B (zh) 2016-05-11
US20180155318A1 (en) 2018-06-07
SMT202300413T1 (it) 2024-01-10
EP3335731A1 (en) 2018-06-20
LT3135286T (lt) 2023-11-10
KR101867633B1 (ko) 2018-06-15
WO2012012542A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
ES2963362T3 (es) 2024-03-26
PT3135286T (pt) 2023-11-28
PT2595484T (pt) 2018-01-22
RS64819B1 (sr) 2023-12-29
PL2595484T3 (pl) 2018-03-30
FI3135286T3 (fi) 2023-11-15
CA3117855C (en) 2023-01-10
EP3335731B1 (en) 2024-09-04
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
CN103220910A (zh) 2013-07-24
EP3135286A1 (en) 2017-03-01
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
NO2595484T3 (enExample) 2018-03-17
JP2017031159A (ja) 2017-02-09
TWI583679B (zh) 2017-05-21
JP6200561B2 (ja) 2017-09-20
EP4494704A3 (en) 2025-04-23
DK2595484T3 (en) 2018-01-22
EP3135286B1 (en) 2023-09-06
HRP20231446T1 (hr) 2024-03-01
US20250179044A1 (en) 2025-06-05
US20220274951A1 (en) 2022-09-01
CA2806017A1 (en) 2012-01-26
EP2595484B1 (en) 2017-10-18
HUE064157T2 (hu) 2024-02-28
PL3135286T3 (pl) 2024-04-22
EP2595484A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20250179044A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20250228838A1 (en) Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
JP2008056697A (ja) Cns疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
KR20250105660A (ko) 울로타론트를 이용한 신경정신 약물 변경 방법
WO2023243659A1 (ja) 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法